Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.